Structure–activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2
Authors:
- Ralf KobersteinRKRalf Koberstein
- Emmanuelle CottreelECEmmanuelle Cottreel
- Amandine BollerABAmandine Boller
- Thomas WellerTWThomas Weller
- John GatfieldJGJohn Gatfield
- Catherine Brisbare-RochCBCatherine Brisbare-Roch
- Francois JenckFJFrancois Jenck
- Christoph BossCBChristoph Boss
- 1 July 2013
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 23 (13) , 3857-3863
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Orexin Receptor Antagonists: A New Concept In CNS Disorders?ChemMedChem, 2010
- Orexin receptor antagonists: a review of promising compounds patented since 2006Expert Opinion on Therapeutic Patents, 2010
- Biomedical Application of Orexin/Hypocretin Receptor Ligands in NeuroscienceJournal of Medicinal Chemistry, 2009
- Orexin Receptor Antagonism: A New Principle in NeuroscienceChimia, 2008
- Orexin Receptor Antagonists: Medicinal Chemistry and Therapeutic PotentialCurrent Topics in Medicinal Chemistry, 2008
- Promotion of sleep by targeting the orexin system in rats, dogs and humansNature Medicine, 2007
- The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 GeneCell, 1999
- Narcolepsy in orexin Knockout MiceCell, 1999
- Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding BehaviorCell, 1998
- The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activityProceedings of the National Academy of Sciences, 1998